Previous 10 | Next 10 |
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medi...
MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He j...
The following slide deck was published by Longeveron Inc. in conjunction with this event. For further details see: Longeveron (LGVN) Investor Presentation - Slideshow
MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Interim Chief Ex...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/PhotobyTawat Pfizer (NYSE: PFE ) and Moderna (NASDAQ: MRNA ) stocks are in the news Wednesday as the FDA approves new booster shots for Covid-19. The new booster shots approved b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Anastasia Zagoruyko Longeveron (NASDAQ: LGVN ) stock is on the move Wednesday after the FDA granted its fast-track designation for Lomecel-B . Lomecel-B is a allogeneic, bone marrow-d...
The shares of clinical-stage biotech Longeveron Inc. ( NASDAQ: LGVN ) jumped in the pre-market trading Wednesday after the company announced that the FDA issued Fast Track Designation for its lead asset Lomecel-B as a treatment for Hypoplastic Left Heart Syndrome (HLHS). A...
MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the U.S. Food and Drug Administration (FDA) ha...
MIAMI, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that the European Patent Office (EPO) has issued a notice of its int...
Longeveron Inc. (LGVN) Q2 2022 Earnings Conference Call August 12, 2022 08:30 AM ET Company Participants Elsie Yau - Stern Investor Relations Chris Min - Interim Chief Executive Officer & Chief Medical Officer James Clavijo - Chief Financial Officer Joshu...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...